Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eliglustat + GM-CSF in Advanced Neuroblastoma
NCT07090538Phase 1Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Aug 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of eliglustat in neuroblastoma, sponsored by Chinese PLA General Hospital. Primary endpoint: Objective Response Rate. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
eliglustat
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT07090538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07090538.